Recipharm establishes long-term supply agreement with Tillotts Pharma

The agreement comprises technology transfer and commercial manufacturing of the products Entocort and Asacol.

The agreement comprises technology transfer and commercial manufacturing of the products Entocort and Asacol. The partnership will also involve the commercial scale development of Tillotts’ ongoing development programme for TP05. All products are part of Tillotts’ dedication to innovative pharmaceutical products in the field of gastroenterology.

Recipharm will provide advanced pellet coating technology for controlled release from its facility in Pessac (France), tablet and capsule manufacturing including final packaging from its facility in Fontaine (France), and bottle filling from its site in Lisbon (Portugal). The total shared investment across the Recipharm network to enable this business amounts to €3.5 million. This includes investments to create new capacity as well as product specific investments.

The collaboration between Recipharm and Tillotts Pharma marks an important step in Recipharm’s full service offering strategy, allowing customers to fulfil their needs for different technologies while working with Recipharm as one full service partner. This approach allows the CDMO to simplify both the technology transfer and scale-up of projects, as well as ongoing commercial supply.

Kjell Johansson, President Manufacturing Services Europe at Recipharm, said: “We are really pleased that Tillotts Pharma has chosen Recipharm for these exciting products and projects. Our technical solutions offer a high level of customisation and we look forward to working with Tillotts to ensure their continued development and success within the gastroenterology area.”

Mattias Norrman, COO of Tillotts Pharma AG, said: “We have undertaken a thorough evaluation process to ensure we partner with a CDMO that can meet the needs we have for project management during technology transfer and scale-up, as well as fulfilling our requirements as a reliable commercial supplier. We believe Recipharm is the ideal CDMO partner for this task and look forward to establishing a long term relationship.”